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For CYP72A1 
Gene Nucleotide Protein Protein 
Identity Identity Similarity 
CYP72C from 55 . O% 49 . 1% 61.5% 
Catharanthus 
CYP72A1 from 53 . 2% 48 . 2% 6O . 3% 
Catharanthus 
CYP72B from 49 . 6% 48 . 6% 6O . 7% 
Catharanthus 
CYP'72A from Nicotiana 52 . 8% 44 . 4% 54 . 0% 
For CYP92A1 
CYP92A2 from Nicotiana 59. 0% 58 . 2% 65 . 6% 
CYP92A3 from Nicotiana 56 . 5% 57 . 6% 64 . 5% 
CYP98A1 from Sorghum 51 . 2% 36 .4% 47 . 3% 
CYP98A2 from Soybean 49 . 0% 38 . 6% 48 . 8% 
CYP'71C2 from Maize 51 . 7% 32 . 8% 43 . 9% 
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CYTOCHROME P450 ENZYMES AND 
RELATED COMPOUNDS AND METHODS 
This application claims priority to US. Provisional 
Patent Application Ser. No. 60/092,596, ?led Jul. 12, 1998. 
BACKGROUND OF THE INVENTION 
Plant cytochrome P450s are noW knoWn to be involved in 
the metabolism and detoxi?cation of numerous pesticides. 
Much of the evidence has been gathered via traditional 
chemistry techniques (Shuler, 15 Crit Rev Plant Sci 235 
(1996); BolWell et al., 37 Phytochemistry 1491(1994) and 
Frear et al., 8 Phytochemistry 2157 (1969)), or through use 
of mammalian or bacterial genes in plants (Shiota et al., 106 
Plant Physiol 17 (1994) and O’Keefe et al., 105 Plant 
Physiol 473 (1994)). 
Recently, hoWever, endogenous plant P450s have been 
cloned and expressed using molecular biology techniques. 
For example, CYP73A1, a cytochrome isolated from J erusa 
lem artichoke Was recently shoWn to metaboliZe chlortolu 
ron (Pierrel, 224 Eur J Biochem 835 (1994). Likewise, 
several soybean P450s Were cloned and one Was shoWn to 
metaboliZe linuron and chlortoluron (Presentation, Weed Sci 
Soc ofAmer (February 1997)). 
The most up-to-date source of information on plant P450s 
is on the internet. As of Jul. 12, 1998, most of the informa 
tion related to the CYP72A subfamily of P450s on that Web 
site pertained to the Catharanthus (rosens) P450s, although 
Nicotiana and Arabidopsis P450s Were also characteriZed. 
The site implied the existence of tWo CYP72 P450s from 
Zea mays, although the sequence information Was not dis 
closed for either. The tWo Were assigned separate identi?ers 
by the Web site developer. Speci?cally, the Web site stated: 
CY P72A Zea mays 
no accession number (318 amino acids) 
Mike Persons and Mary Schuler 
PCR 4 formerly CYp95A1 (missnamed due to a frame 
shift in the PCR fragment) 
CPY72A1 Zea mays (maiZe) 
no accession number 
Mike Barrett 
clone A8 most like PCR fragment PCR4 from Mike 
Persans and Mary Schuler. The PCR4 fragment Was 
missnamed as CYP95A1 due to a frame shift error in 
the sequence in the I helix region, also like Arabi 
dopsis GSS BAC end fragment B24203 (67? 
identical) submitted to nomenclature committee. 
The above can be found at http://drnelson.utmem.edu/ 
biblioD.html#72A. 
The concept of a multiple pesticide metaboliZing P450 in 
corn Was ?rst proposed during the Ph.D. Dissertation of 
Laura Boldt on Apr. 15, 1992. FIG. 12 in the present 
disclosure is the table from her thesis, Which indicates that 
corn line GA209 is not only sensitive to bentaZon, but also 
to the herbicides imaZethapyr, nicosulfuron and primisulfu 
ron. In further research by Roger Baerg, it Was shoWn that 
the in-vitro metabolism of the herbicides nicosulfuron, 
chlorimuron, bentaZon, imaZethapyr, and the insecticide 
malathion are all inhibited by the insecticide terbufos 
sulfone (FIG. 13—from Baerg et al., 55 Pesticide Biochem 
istry and Physiology 10 (1996), initially disclosed Nov. 4, 
1994 in dissertation form). 
Citation of the above documents is not intended as an 
admission that any of the foregoing is pertinent prior art. All 
statements as to the date or representation as to the contents 
of these documents is based on subjective characteriZation 
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of information available to the applicant, and does not 
constitute any admission as to the accuracy of the dates or 
contents of these documents. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to provide 
compounds useful to protect plants from the otherWise 
detrimental effects of a broad spectrum of pesticides, includ 
ing negative effects of herbicides and/or insecticides. 
It is a further object to provide assays for discovery of 
neW pesticide safeners, including herbicide and/or insecti 
cide safeners. 
It is yet another object to provide assays for discovery of 
neW pesticides, including herbicide and/or insecticide 
assays. 
It is yet another object to provide tools for pesticide 
metabolite analysis, including herbicide and/or insecticide 
metabolite analysis. 
Moreover, for the purposes of the present invention, the 
term “a” or “an” entity refers to one or more of that entity; 
for example, “a protein” or “a nucleic acid molecule” refers 
to one or more of those compounds or at least one com 
pound. As such, the terms “a” (or “an”), “one or more” and 
“at least one” can be used interchangeably herein. It is also 
to be noted that the terms “comprising”, “including”, and 
“having” can be used interchangeably. Furthermore, a com 
pound “selected from the group consisting of” refers to one 
or more of the compounds in the list that folloWs, including 
mixtures (i.e., combinations) of tWo or more of the com 
pounds. According to the present invention, an isolated, or 
biologically pure, protein or nucleic acid molecule is a 
compound that has been removed from its natural milieu. As 
such, “isolated” and “biologically pure” do not necessarily 
re?ect the extent to Which the compound has been puri?ed. 
An isolated compound of the present invention can be 
obtained from its natural source, can be produced using 
molecular biology techniques or can be produced by chemi 
cal synthesis. In this application, the term “pesticide” is used 
as a generic Word for both herbicides and insecticides. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is the DNA (SEQ ID NO 1) and deduced amino 
acid sequence (SEQ ID NO 2) of CY P72A1. 
FIG. 2 is the DNA (SEQ ID NO 3) and deduced amino 
acid sequence of CYP92A1 (SEQ ID NO 4); and 
FIG. 3 is a spectra demonstrating expression of 72A1 in 
yeast microsomes; and 
FIG. 4 shoWs comparisons of nucleotide and protein 
identity of CYP72A1 and CYP92A1 With knoWn sequences. 
It also shoWs protein similarity of CY P72A1 and CYP92A1 
With knoWn sequences; and 
FIG. 5 is a genomic blot shoWing induction of expression 
of CY72A1 and CYP92A1 by NA-treatment; and 
FIG. 6 is the hybridiZation pattern of CYP72A1; and 
FIG. 7 is the hybridiZation pattern of CYP92A1; and 
FIG. 8 shoWs chromatographs of the production of the 
bentaZon metabolites, in comparison to appropriate control 
treatments; and 
FIG. 9 shoWs chromatographs of the production of the 
chlortoluron metabolites, in comparison to appropriate con 
trol treatments; and 
FIG. 10 shoWs chromatographs of the production of the 
malathion metabolites, in comparison to appropriate control 
treatments; and 
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FIG. 11 shows chromatographs of the production of the 
chlorimuron metabolites, in comparison to appropriate con 
trol treatments. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides, inter alia, nucleic acids 
Which encode P450s in corn that, When expressed in the 
presence of a reductase, metabolize compounds exemplary 
of several distinct classes of insecticides and herbicides. The 
CYP72A1 P450 has been shoWn to metaboliZe the herbi 
cides bentaZon (tradename Basagran), chlorimuron 
(tradename Classic and others), and chlortoluron (used in 
Europe), and the insecticide malathion (marketed under 
many tradenames). Representative chromatographs shoWing 
the production of the metabolites, in comparison to appro 
priate control treatments, are shoWn in FIGS. 8—11. 
The above pesticides are representative of unclassi?ed 
heterocyclic herbicides (bentaZon), sulfonylurea herbicides 
(chlorimuron), substituted urea herbicides (chlortoluron), 
and organophosphate insecticides (malathion). The 
CYP72A1 P450 thus displays a broad substrate range. Based 
on genetic and biochemical data gathered prior to the 
cloning and expression of the CYP72A1 P450, additional 
substrates in the sulfonylurea family of herbicides 
(particularly nicosulfuron, primisulfuron, prosulfuron, and 
rimsulfuron), the herbicide imaZethapyr (tradename Pursuit 
and others, from the imidaZolinone family of herbicides), the 
herbicide fumetsulam (tradename Broadstrike and others, 
from the triaZolopyrimidine family of herbicides), experi 
mental herbicides under development related to 
sulcantrione, and other organophosphate insecticides Would 
be metaboliZed by the CYP72A1 P450. HoWever, the 
CYP72A1 P450 does not metaboliZe all substrates Which 
have been tested. UnmetaboliZed substrates include the 
herbicides alachlor, 2,4-D, linuron, dicamba and chlorsul 
furon. 
The present invention can be used in the development of 
herbicide resistant crops. For instance, crops transformed 
With SEQ ID NO 1 Would be resistant to herbicides from 
several herbicide chemical families having different sites of 
action. Historically, herbicide resistant crops that have been 
developed are resistant to only one chemical family or 
inhibitors of one site of action. The present invention 
overcomes many of the limitations of previously developed 
herbicide resistant crops. In addition, the invention can be 
used in the discovery and development of neW herbicides 
and other pesticides. 
The gene can also be expressed in other plants, such as 
Arabidopsis thaliana, or in a heterologous system, such as 
yeast cells, to demonstrate and study the metabolism of 
candidate pesticide molecules by the CYP72A1 P450. The 
present invention can also be used to generate P450 
produced pesticide metabolites needed for pesticide regis 
tration studies. Moreover, the present invention includes the 
use of the nucleic acid compounds to generate nucleic acid 
probes to test for the induction activity of neW candidate 
safeners. It can also provide probes and primers for identi 
?cation of additional P450s. 
Therefore, the present invention includes nucleic acid 
compounds comprising SEQ ID NO 1. The nucleic acid 
Which is SEQ ID NO 1 is preferred. HoWever, portions of 
SEQ ID NO 1 are also provided for the use as primers and 
probes for molecular biology research or chemical assays. 
Vectors comprising the nucleic acids, in particular, SEQ 
ID NO 1 are also provided. Vectors may be obtained from 
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various commercial sources, including Clontech 
Laboratories, Inc. (Palo Alto, Calif.), Stratagene (La Jolla, 
Calif.), Invitrogen (Carlsbad, Cailf.), NeW England Biolabs 
(Beverly, Mass.) and Promega (Madison, Wis.). Preferred 
vectors are those Which are capable of transferring the 
sequences disclosed herein into plant cells or plant parts. 
Also provided are cells comprising the nucleic acids, in 
particular, SEQ ID NO 1. Preferred cells are eukaryotic 
cells. Most preferred are yeast (the Saccharomycetes) and 
plants. Any species of yeast are consider Within the scope of 
the present invention; hoWever, S. cerevisiae cells are pre 
ferred. The most preferred strains are WAT 11 and WAT 21, 
With WAT 11 preferred as betWeen the tWo. 
Included Within the scope of the present invention, With 
particular regard to the nucleic acids above, are allelic 
variants, degenerate sequences and homologues. The present 
invention also includes variants due to laboratory 
manipulation, such as, but not limited to, variants produced 
during polymerase chain reaction ampli?cation or site 
directed mutagenesis. It is also Well knoWn that there is a 
substantial amount of redundancy in the various codons 
Which code for speci?c amino acids. Therefore, this inven 
tion is also directed to those nucleic acid sequences Which 
contain alternative codons Which code for the eventual 
translation of the identical amino acid. Also included Within 
the scope of this invention are mutations either in the nucleic 
acid sequence or the translated protein Which do not sub 
stantially alter the ultimate physical properties of the 
expressed protein. For example, substitution of valine for 
leucine, arginine for lysine, or asparagine for glutamine may 
not cause a change in functionality of the polypeptide. 
Lastly, a nucleic acid sequence homologous to the exempli 
?ed nucleic acid molecules (or allelic variants or degener 
ates thereof) may have at least 85%, preferably 90%, and 
most preferably 95% sequence identity With a nucleic acid 
molecule in the sequence listing. 
It is knoWn in the art that there are commercially available 
computer programs for determining the degree of similarity 
betWeen tWo nucleic acid sequences. These computer pro 
grams include various knoWn methods to determine the 
percentage identity and the number and length of gaps 
betWeen hybrid nucleic acid molecules. Preferred methods 
to determine the percent identity among amino acid 
sequences and also among nucleic acid sequences include 
analysis using one or more of the commercially available 
computer programs designed to compare and analyZe 
nucleic acid or amino acid sequences. These computer 
programs include, but are not limited to, GCGTM (available 
from Genetics Computer Group, Madison, Wis.), DNAsisTM 
(available from Hitachi SoftWare, San Bruno, Calif.) and 
MacVectorTM (available from the Eastman Kodak Company, 
NeW Haven, Conn.). A preferred method to determine per 
cent identity among amino acid sequences and also among 
nucleic acid sequences includes using the Compare function 
by maximum matching Within the program DNAsis Version 
2.1 using default parameters. 
In another embodiment of the present invention, a pre 
ferred nucleic acid molecule includes an isolated nucleic 
acid molecule Which is at least about 50 nucleotides, or at 
least about 150 nucleotides, and Which hybridiZes under 
conditions Which preferably alloW about 50% base pair 
mismatch, more preferably under conditions Which alloW 
about 45% base pair mismatch, more preferably under 
conditions Which alloW about 40% base pair mismatch, 
more preferably under conditions Which alloW about 35% 
base pair mismatch, more preferably under conditions Which 
alloW about 30% base pair mismatch, more preferably under 
US 6,380,465 B1 
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conditions Which allow about 25% base pair mismatch, 
more preferably under conditions Which allow about 20% 
base pair mismatch, more preferably under conditions Which 
alloW about 15% base pair mismatch, more preferably under 
conditions Which alloW about 10% base pair mismatch and 
even more preferably under conditions Which alloW about 
5% base pair mismatch With a nucleic acid molecule 
selected from the group consisting of SEQ ID NO 1 and 
SEQ ID NO 3. 
Also Well knoWn to those skilled in the art is hoW 
base-pair mismatch, i.e. differences betWeen tWo nucleic 
acid molecules being compared, including non 
complementarity of bases at a given location, and gaps due 
to insertion or deletion of one or more bases at a given 
location on either of the nucleic acid molecules being 
compared, Will affect Tm or Td for nucleic acid molecules of 
different siZes. For example, Tm decreases about 1° C. for 
each 1% of mismatched base-pairs for hybrids greater than 
about 150 bp, and Td decreases about 5° C. for each 
mismatched base-pair for hybrids beloW about 50 bp. Con 
ditions for hybrids betWeen about 50 and about 150 base 
pairs can be determined empirically and Without undue 
experimentation using standard laboratory procedures Well 
knoWn to those skilled in the art. These simple procedures 
alloW one skilled in the art to set the hybridiZation conditions 
(by altering, for example, the salt concentration, the forma 
mide concentration or the temperature) so that only nucleic 
acid hybrids With less than a speci?ed % base-pair mismatch 
Will hybridiZe. Stringent hybridiZation conditions are com 
monly understood by those skilled in the art to be those 
experimental conditions that Will alloW hybridiZation 
betWeen molecules having about 30% or less base-pair 
mismatch (i.e., about 70% or greater identity). Because one 
skilled in the art can easily determine Whether a given 
nucleic acid molecule to be tested is less than or greater than 
about 50 nucleotides, and can therefore choose the appro 
priate formula for determining hybridiZation conditions, he 
or she can determine Whether the nucleic acid molecule Will 
hybridiZe With a given gene under stringent hybridiZation 
conditions and similarly Whether the nucleic acid molecule 
Will hybridiZed under conditions designed to alloW a desired 
amount of base pair mismatch. 
Transformation of cells With the compounds of the present 
invention can be accomplished according to knoWn proce 
dures. For example, infective, vector-containing bacterial 
strains (such as Agrobacterium rhizogenes and Agrobacte 
rium tumefaciens) may be used for transformation. 
Zambryski, 43 Ann. Rev. Pl. Physiol. Pl. Mol. Biol. 465 
(1992). The folloWing procedures are also Well-knoWn: 
Pollen-tube transformation [Zhon-xun et al., 6 Plant Molec. 
Bio. 165 (1988)]; direct transformation of germinating seeds 
[Toepfer et al., 1 Plant Cell 133 (1989)]; polyethylene glycol 
or electroporation transformation [Christou et al., 84 Proc. 
Nat. Acad. Sci. 3662 (1987)]; and biolistic processes [Yang 
& Cristou, Particle Bombardment Technology for Gene 
Transfer (1994)]. The transformed cells are also Within the 
scope of the present invention. 
The transformed cells may be induced to form trans 
formed plants via organogenesis or embryogenesis, accord 
ing to the procedures of Dixon Plant Cell Culture: A 
PracticalApproach (IRL Press, Oxford 1987). 
Moreover, any plants or plant cells or parts are Within the 
scope of the present invention. For instance, Whole plants, 
embryos and seeds are considered part of the present 
invention, as Well as shoots, ?oWers, leaves, leaf tips and the 
like. The most preferred plant is maiZe, although any of the 
folloWing plants are also Within the scope of the present 
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invention: soybean, beet, tobacco, Wheat, barley, poppy, 
rape, sun?ower, alfalfa, sorghum, rose, carnation, gerbera, 
carrot, tomato, lettuce, chicory, pepper, melon and cabbage. 
In another aspect of the present invention, there are 
included nucleic acid compounds comprising SEQ ID NO 3. 
Eukaryotes comprising a nucleic acid compound of SEQ ID 
NO 3 is speci?cally provided. MaiZe is the preferred eukary 
ote. 
The present invention also provides methods to determine 
the ability of a test compound to protect a plant from the 
deleterious effects of a pesticide, comprising a ?rst step of 
contacting the test compound With a eukaryote of the present 
invention, and a second step of determining if the eukaryote 
is induced to produce a nucleic acid of the present invention, 
in particular, SEQ ID NO 1, RNA transcribed therefrom, or 
SEQ ID NO 2. Those in the art realiZe that the second step 
can be accomplished by routine means, such as, but not 
limited to, PCR analysis, genomic southern blot analysis, or 
Western blot analysis. 
Other methods herein provided are those useful for deter 
mining the ability of a test compound to be metaboliZed by 
a eukaryote of the present invention, comprising a ?rst step 
of contacting the eukaryote With the test compound and a 
second step of determining the existence of metabolites. As 
above, detection of metabolites is routine in the art. For 
example, the test compound can carry a physical label, 
usually a radioactive or ?uorescent label. Typical radioactive 
labels are 3H, 14C and 23P. 
Also provided are methods to express an amino acid 
compound of the present invention, comprising transform 
ing a eukaryote With a SEQ ID NO 1, and inducing SEQ ID 
NO 1 With napthalic acid. 
In another embodiment, there are provided methods to 
cause pesticide resistance in a plant, comprising causing the 
plant to express an amino acid compound of claim 14, 
provided that the pesticide to Which the plant is resistant is 
selected from the group consisting of: heterocyclic 
herbicides, sulfonylurea herbicides, substituted urea herbi 
cides and organophosphate insecticides. 
Lastly, the present invention includes methods to alter the 
naturally-occurring expression pattern of the nucleic acids 
provided so as to either delay or speed expression. In 
particular, in order to practice the altered expression pattern 
aspect of the present invention, one Would construct a vector 
Which provided for either an early or late promoter in 
conjunction With the present sequences. For instance, the 
folloWing promoters Would be useful in early expression of 
the present sequences: 
Ogs4B (Tsuchiya et al., 36 Plant Cell Physiology 487 
(1994) 
TA29 (KoltunoW et al., 2 Plant Cell 1201 (1990) 
A3 & A9 (Paul et al., 19 Plant Molecular Biology 611 
(1992) 
In order to then constitutively express the sequences 
described above, the construct optionally contains, for 
example, a 35S promoter. Transformation of plants With 
these sequences Would be according to knoWn procedures as 
described above. Plants can be groWn according to knoWn 
procedures. 
Proteins Which Would result from expression of the 
nucleic acid molecules herein disclosed are preferred, With 
the proteins Which Would result from expression of the 
exempli?ed compounds being most preferred. It is under 
stood that proteins Which Would result from expression of 
allelic variants of the exempli?ed sequences, as Well as 
proteins Which Would result from the expression of nucleic 
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acid molecules Which hybridize under stringent hybridiZa 
tion conditions to the nucleic acid molecules exempli?ed are 
Within the scope of the present invention as Well. Lastly, an 
amino acid sequence substantially homologous to a referent 
protein Will have at least 85% sequence identity, preferably 
90%, and most preferably 95% sequence homology With the 
amino acid sequence of a referent protein or a peptide 
thereof. For example, an amino acid sequence is substan 
tially homologous to a referent P450 protein if, When aligned 
With a referent P450 protein, at least 85% of its amino acid 
residues are the same. Speci?cally provided are amino acid 
compounds comprising SEQ ID NO 2 and/or SEQ ID NO 3. 
The minimal siZe of a protein homolog of the present 
invention is a siZe sufficient to be encoded by a nucleic acid 
molecule capable of forming a stable hybrid (i.e., hybridiZe 
under stringent hybridiZation conditions) With the comple 
mentary sequence of a nucleic acid molecule encoding the 
corresponding natural protein. As such, the siZe of the 
nucleic acid molecule encoding such a protein homolog is 
dependent on nucleic acid composition and percent homol 
ogy betWeen the nucleic acid molecule and complementary 
sequence. It should also be noted that the extent of homol 
ogy required to form a stable hybrid can vary depending on 
Whether the homologous sequences are interspersed 
throughout the nucleic acid molecules or are clustered (i.e., 
localiZed) in distinct regions on the nucleic acid molecules, 
The minimal siZe of such nucleic acid molecules is typically 
at least 12 to about 15 nucleotides in length if the nucleic 
acid molecules are GC-rich and at least about 15 to about 17 
bases in length if they are AT-rich. As such, the minimal siZe 
of a nucleic acid molecule used to encode a protein homolog 
of the present invention is from about 12 to about 18 
nucleotides and may be 25 nucleotides in length. Thus, the 
minimal siZe of a cytochrome P450 protein homolog of the 
present invention is from about 4 to about 6 amino acids in 
length. There is no limit, other than a practical limit, on the 
maximal siZe of such a nucleic acid molecule in that the 
nucleic acid molecule can include gene, and entire gene, 
multiple genes, or portions thereof. The preferred siZe of a 
protein encoded by a nucleic acid molecule of the present 
invention depends on Whether a full-length, fusion, multi 
valent or functional portion of such a protein is desired. 
Preferably, the preferred siZe of a protein encoded by a 
nucleic acid molecule of the present invention is a portion of 
the protein that Which is at least 30 amino acids, more 
preferably at least 35 amino acids and even more preferably 
at least 45 amino acids in length. 
EXAMPLES 
Example 1 
Cloning, Sequencing and Estimating Copy Number of 
MaiZe P450s 
A maiZe cDNA library Was constructed from napthalic 
anhydride (NA)-treated Pioneer 3343IR 3.5-day-old seed 
lings using lambda-ZAPII vector kit (Stratagene). 
The library Was screened under high stringency condi 
tions by tWo P450 clones generated by PCR to heme-binding 
region and inducible by naptalic acid. Both PCR products 
Were labeled With [32P]-dCTP by random priming method. 
Clones Were separated into tWo subsets based on the simi 
larity of the sequencing information. The longest clones 
from each subset Were completely sequenced. Both clones 
Were truncated at the 5‘-end. The library Was rescreened 
using the longer clones. One of the genes Was recovered as 
a full length (CYP72A1), Whereas the second gene 
(CYP92A1) Was still truncated. 
Northern blot analysis Was performed With total RNA 
isolated from control and agarose gel electrophoresis and 
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hybridiZed under high stringency conditions. To estimate the 
copy number, Southern blot analysis Was performed using 
genomic DNA from 3343IR maiZe Which Was digested With 
SacI EcoRV, EcoRI, HindIII, and BamHI. The analysis Was 
carried out under high stringency (65 degrees Celsius in 
0.1><SSC and 0.1% SDS). 
Example 2 
Expression and Sequence Con?rmation of MaiZe P450s in 
Yeast 
Both genes (CYP72A1 and CYP92A1), obtained as 
described in Example 1, Were introduced into pYeDP60 
vector for yeast expression. CYP72A1 Was introduced as a 
full length gene With in-frame Met 1 and 8 as the start 
codons, While CYP92A1 Was modi?ed for the expression. 
Approximately 8><106 plaque-forming units Were 
screened by tWo P450 fragments. 73 positive clones Were 
isolated and sequenced. Sequence homology Was used to 
separate these clones into tWo groups. Secondary screening 
using the cDNA inserts from the longest clones identi?ed an 
additional 56 clones Which Were sequenced at the ends. All 
the sequences represented one of the tWo genes. CYP 72A1 
Was isolated presumably as a full-length gene, hoWever, 
CYP92A1 Was still missing 30—50 bases at the amino 
terminus after rescreening. These genes and their deduced 
amino acid sequences shoWed homology to several plant 
P450s. See FIG. 4. 
Example 3 
Induction of CYP72A1 and CYP92A1 by Napthalic Acid 
and Con?rmation of Copy Number 
The expression of both genes (CYP72A1 and CYP92A1) 
Was induced by NA-treatment, but to different extents: 
CYP72A1 Was highly induced, Whereas CYP92A1 Was 
induced signi?cantly less (FIG. 5). Based on the results of 
the genomic Southern blot analysis, the hybridiZation pat 
terns Were consistent With those predicted from the restric 
tion patterns of the corresponding cDNAs. Distinct patterns 
indicated that individual probes did not cross-hybridiZe to 
other P450 genes ad shoWed that CYP72A1 is likely to be 
present as tWo copies in the genome of 3343IR maiZe, and 
CYP92A1 as a single copy (FIGS. 6 & 7). Certain physico 
chemical characteristics for the deduced proteins, antigenic 
ity and secondary structure Were calculated using NetWork 
Protein Sequence Analysis at IBCP, France. 
Example 4 
Optional Strategies for Cloning and Expressing CYP72A1 
and CYP92A1 
Prepare RNA from NA-induced maiZe shoots. One or 
more of the folloWing techniques can then be used: primers 
can be designed from the ?anking heme region according to 
Ohbayashi et al, 1993. Alternatively, degenerate 5‘ primers 
to heme region may be uses, With 3‘ primer to the poly Atail, 
according to Meij er et al., 1993). Another acceptable method 
is to use nested PCR, With the ?rst round using 5‘ primer to 
region upstream from heme region, according to Frey et al., 
1995. 
Clone selection criteria can include identi?cation of 
induction of message With NA, identi?cation of RFLP 
co-segregation With phenotypes in repulsion phase homoZy 
gotes and/or differential expression betWeen GA209 and ie. 
B73 (Wild type). 
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Expression strategies include using both full length or 
truncated (Met 8 start site) CYP72A1 cDNA in yeast strains 
WATll, WAT21 W (R) from Philippe Urban and Denis 
Pornpon, With, optionally, yeast vector pYeDP60. Expres 
10 
incubated With [14C]-labeled substrates and products ana 
lyZed by HPLC. 
sion is ideall achieved With full len th cDNA and WATll. 5 . . . 
Expression nliay also require 36 hougs rather than 24 hours Althollgh the present menu?“ has been fully descllbed 
of galactose induction prior to rnicrosorne preparation. Glu- hereln’ It IS to be noted that V_anOu_S Changes and modl?ca' 
C056 ($61) or galactose (SL1) media prior to induction Win tions are apparent to those skilled in the art. Such changes 
give expression and rnodi?cations are to be understood as included Within 
Metabolisrn experiments can be accomplished using 10 the 560116 0f the present invention as de?ned by the 
rnicrosornes prepared from yeast cells. The substrates can be appended claims. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 4 
<2 10> SEQ ID NO 1 
<211> LENGTH: 1584 
<2 12> TYPE: DNA 
<213> ORGANISM: Zea mays 
<400> SEQUENCE: l 
atggcgacct gcgatctgct gatgctgcgg gaagcatctc cgtgggcgct ggccggcgcg 60 
gtggcgtccg tgtcgctgtt gtggctggtg gcctggacgc tggagtgggc ctggtggaca 120 
ccttggcggc tcgatcgggc cctgcgggcc cagggcctca atggcaccag gtaccgcctc 180 
ttcaccggcg acctgaggga aaccgcccgg gttaaccggg aggctcgcaa gaagccgctg 240 
ccgctcggct gccacgacat caccccacgc gtgcagccca tgcatcacag caccatcaag 300 
gaatacggga aactatcgtt cacctggttc ggcccaacac caagggtgat gattcctgac 360 
ccagagttag tcaaagaggt gctgtctaat aagtttggcc actttggcaa accaaggagt 420 
agccgcattg ggaggttgct agccaacggg cttgtaaatc atgatggtga aaaatgggca 480 
aagcacagga gaattcttaa tcctgcattt caccatgaaa aaataaaggg gatgatgcca 540 
gtattttcta cctgctgtat tgaaatgatt actagatggg ataattcaat gtcttccgag 600 
ggatcttctg agatagatgt ctggcctgag ttccagaatc ttactggaga tgttatctca 660 
agaactgcgt ttgggagcaa ctatcaagaa gggaggagaa tttttgagct acaaggagaa 720 
ctagctgaac gcctcatcca atctgttcag acaatattta tcccaggcta ttggttcttg 780 
cccaccaaaa acaacagaag gatgagagca atcgatgtag agatccgcaa aattctccgt 840 
gaaataattg ggaagagaga gaaggatact aaaaacagag aaacaaataa agatgacttg 900 
ctgggcttat tactggagtc aaacacaagg caatcaaatg gaaatgcaag cctgggattg 960 
acaacagaag atgtgattga ggaatgcaag ttattttact ttgcaggtat ggagacaaca 1020 
tcagtcctgc ttacttggac acttattgtg ctaagcatgc acccagaatg gcaagagaga 1080 
gcaagagaag aggttttgag ccactttgga agaaccacac cagattatga tagcttgagc 1140 
cgcctcaaga ctgtaaccat gattctacat gaggtcctta ggttgtaccc accggcaacc 1200 
tttctaacca gaagaactta taaggaaatg gagctcggtg gaatcaaata tcctgcagga 1260 
gtggagctcc ttctgcccgt catcttcatt caccatgatc ccgacatttg gggaaaagac 1320 
gcaagcgagt tcaacccaga aaggtttgcc aacggcatct ccagcgcaac caggcatcag 1380 
gctgctttct ttccgttcgg agggggcccc aggatctgca tcggccagag ctttgcgttg 1440 
ctggaagcca agatgacgct atgcaccatc ctccagcgct tctcgttcga gctctcacca 1500 
tcctacaccc acgcgccgta caccgtgata acactgcacc ctcagcacgg tgctcagata 1560 
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Ile 
Asp 
Glu 
Asp 
225 
Arg 
Leu 
Ala 
Leu 
Leu 
305 
Val 
Glu 
Leu 
Val 
Thr 
385 
Asn 
Glu 
His 
Gly 
Leu 
465 
Leu 
Leu 
Ala 
Ser 
Gly 
Met 
210 
Tyr 
Met 
Asp 
Lys 
Glu 
290 
Ile 
Ser 
Leu 
Pro 
His 
370 
Ser 
Val 
Phe 
Asp 
Ile 
450 
His 
Ser 
Met 
Arg 
Glu 
195 
Val 
Ile 
Lys 
Val 
Asp 
275 
Val 
Ile 
Glu 
Asn 
Arg 
355 
Pro 
Val 
Trp 
Arg 
Phe 
435 
Asn 
Gly 
Met 
Val 
Ile 
180 
Gly 
Asp 
Pro 
Arg 
His 
260 
Met 
Gln 
Ala 
Leu 
His 
340 
Leu 
Ala 
Asp 
Ala 
Pro 
420 
Gln 
Leu 
Phe 
Asp 
Val 
500 
165 
Val 
Asp 
Glu 
Trp 
Met 
245 
Asn 
Leu 
Leu 
Gly 
Leu 
325 
Val 
Pro 
Ala 
Gly 
Ile 
405 
Glu 
Leu 
Ala 
Glu 
Glu 
485 
Ala 
Leu 
Ser 
Phe 
Leu 
230 
Lys 
Glu 
Asp 
Ser 
Thr 
310 
Lys 
Ile 
Tyr 
Pro 
Tyr 
390 
Gly 
Arg 
Leu 
Leu 
Trp 
470 
Ala 
Glu 
Gly 
Ala 
Phe 
215 
Asp 
Ala 
Arg 
Val 
Arg 
295 
Asp 
Asn 
Arg 
Ile 
Met 
375 
Asp 
Arg 
Phe 
Pro 
Lys 
455 
Arg 
Phe 
Pro 
Lys 
Pro 
200 
Ala 
Trp 
Arg 
Arg 
Leu 
280 
Asp 
Ser 
Pro 
Pro 
Glu 
360 
Leu 
Val 
Asp 
Val 
Phe 
440 
Val 
Leu 
Lys 
Arg 
Lys 
185 
Ala 
Leu 
Leu 
Phe 
Leu 
265 
Leu 
Asn 
Asn 
Lys 
Asp 
345 
Ala 
Ala 
Leu 
Pro 
Glu 
425 
Gly 
Met 
Pro 
Leu 
Leu 
505 
170 
Tyr 
Ile 
His 
Asp 
Gly 
250 
Arg 
Gln 
Val 
Ala 
Ile 
330 
Arg 
Val 
Pro 
Ala 
Gly 
410 
Ser 
Ser 
Ala 
Asp 
Ala 
490 
Pro 
Val 
Thr 
Gly 
Leu 
235 
Arg 
Glu 
Leu 
Lys 
Asn 
315 
Leu 
Leu 
Leu 
His 
Gly 
395 
Leu 
Lys 
Gly 
Leu 
Gly 
475 
Val 
Ala 
Met 
Pro 
Ala 
220 
Gln 
Phe 
Gly 
Ala 
Ala 
300 
Thr 
Ala 
Val 
Lys 
Val 
380 
Thr 
Trp 
Ile 
Arg 
Ser 
460 
Val 
Pro 
Arg 
Glu 
Ala 
205 
Phe 
Gly 
Leu 
Gly 
Asp 
285 
Ile 
Leu 
Lys 
Thr 
Glu 
365 
Ala 
Val 
Asp 
Asp 
Arg 
445 
Leu 
Thr 
Arg 
Leu 
Glu 
190 
Glu 
Asn 
Tyr 
Glu 
Asn 
270 
Thr 
Glu 
Ala 
Glu 
350 
Thr 
Arg 
Leu 
Ala 
Val 
430 
Met 
Ala 
Ala 
Lys 
Tyr 
510 
175 
Ala Ala 
Phe 
Ile Gly 
Val Ala 
240 
Arg Val 
255 
Phe 
Thr Ser 
Gln Asp 
Ala 
320 
Trp 
Met 
335 
Glu 
Ser Asp 
Met Arg 
Glu Asp 
Phe Ile 
400 
Pro Glu 
415 
Arg Gly 
Cys Pro 
Asn Leu 
Glu Glu 
480 
Phe 
495 
Pro 
Thr Gly 
What is claimed is: 
1. An isolated nucleic acid molecule, Wherein said nucleic 
acid molecule comprises a nucleic acid sequence selected 
from the group consisting of: 
(a) a nucleic acid sequence Which has at least 95% identity 
to SEQ ID NO: 1, Wherein said identity can be deter 
mined using the DNAsis computer program and default 
parameters; and 
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(b) a nucleic acid sequence Which has at least 95% 
identity to SEQ ID NO:3, Wherein said identity can be 
determined using the DNAsis computer program and 
default parameters; Wherein the nucleic acid sequences 
of (a) and (b) each encodes an amino acid having 
cytochrome P450 activity. 
2. A vector comprising a nucleic acid molecule of claim 
1. 
3. A cell transformed With a nucleic acid molecule of 
claim 1. 

